Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsStephen From - CEO & DirectorSarah Romano - ...
Delivered Adjusted EBITDA Above Midpoint of Guidance Range Third Quarter Revenue Growth of 8.7%; Revenue Growth on a Constant ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...
Running a business today demands more than just skill and passion, it requires smart, streamlined tools that make admin tasks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback